Delcath Systems Inc (NAS:DCTH)

$ 11.88 0.66 (5.88%) Market Cap: 379.85 Mil Enterprise Value: 368.93 Mil PE Ratio: 0 PB Ratio: 38.82 GF Score: 66/100

Q3 2024 Delcath Systems Inc Earnings Call Transcript
Nov 08, 2024

$11.06 (+1.10%)

Earnings
Q2 2024 Delcath Systems Inc Earnings Call Transcript
Aug 05, 2024

$8.29 (+2.09%)

Earnings
Q1 2024 Delcath Systems Inc Earnings Call Transcript
May 14, 2024

$7.07 (+30.93%)

Earnings
Q4 2023 Delcath Systems Inc Earnings Call Transcript
Mar 26, 2024

$4.61 (-1.07%)

Earnings
Q3 2023 Delcath Systems Inc Earnings Call Transcript
Nov 13, 2023

$2.98 (+1.02%)

Earnings
Delcath Systems Inc at Lytham Partners Fall Investor Conference Transcript
Oct 17, 2023
Delcath Systems Inc Annual Shareholders Meeting Transcript
Jun 12, 2023
Delcath Systems Inc at Lytham Partners Spring Investor Conference (Virtual) Transcript
May 18, 2023
Q1 2023 Delcath Systems Inc Earnings Call Transcript
May 12, 2023

$6 (-0.75%)

Earnings
Q3 2022 Delcath Systems Inc Earnings Call Transcript
Nov 08, 2022

$2.79 (-7.00%)

Earnings
Delcath Systems Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Q1 2022 Delcath Systems Inc Earnings Call Transcript
May 10, 2022

$5.3 (-8.62%)

Earnings
Delcath Systems Inc Annual Shareholders Meeting Transcript
May 04, 2022
Delcath Systems Inc at Lytham Partners Spring Investor Conference (Virtual) Transcript
Apr 04, 2022
Q4 2021 Delcath Systems Inc Earnings Call Transcript
Mar 25, 2022

$6.19 (-2.06%)

Earnings
Q3 2021 Delcath Systems Inc Earnings Call Transcript
Nov 09, 2021

$11.42 (+2.42%)

Earnings
Q3 2020 Delcath Systems Inc Earnings Call Transcript
Nov 11, 2020

$11.51

Earnings
Delcath Systems Inc Call with Dr. Jonathan Zager, Principal Investigator for Delcath's Ph3 FOCUS Study Transcript
Sep 30, 2020
Q2 2020 Delcath Systems Inc Earnings Call Transcript
Aug 13, 2020

$12.4 (-2.82%)

Earnings

Delcath Systems Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 12:30PM GMT

Release Date Price: $4.17 (-1.18%)

Transcript

Unidentified Participant

Good day, and thanks for joining us to have a conversation with Gerard Michel, CEO of Delcath. Delcath is an interventional oncology company that's developing in minimally invasive percutaneous perfusion technology to treat primary and secondary tumors of the liver. The company, under Gerard, has completed analysis of the Phase 3 study and is expected to file the NDA in the fourth quarter and recently have started commercializing the product in EU with its own sales force.

So to talk about the company's strategy for '22 and beyond, I welcome Gerard to this fireside chat with me. Gerard, glad to see you.

Gerard Michel

Delcath Systems, Inc. - CEO & Director

RK, (inaudible) Thank you for having me.

Unidentified Participant;Gerard Michel

Delcath Systems, Inc. - CEO & Director<

And appreciate you accepting our invitation to join us. So Gerard, just to set up the stage for the audience here and help us familiarize with Delcath's business strategy, if you can start.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.